Humoral Immune Response of SARS-CoV-2-Infected Patients with Cancer: Influencing Factors and Mechanisms.
Miguel Esperança-MartinsLisa GonçalvesInês Soares-PinhoAndreia GomesMarta SerranoBirte BlankenhausPatrícia Figueiredo-CamposAna Catarina-MarquesAna Castro-BarbosaAna CardosoPedro Antunes-MeirelesHenrique Atalaia-BarbacenaPedro GasparPatrícia Howell-MonteiroAntónio Pais-de-LacerdaCatarina MotaMarc VeldhoenPublished in: The oncologist (2021)
These results place the spotlight on patients with cancer, particularly those actively treated with chemotherapy. These patients may potentially be more vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, so it is important to provide oncologists further theoretical support (with concrete examples and respective mechanistic correlations) for the decision of starting, maintaining, or stopping antineoplastic treatments (particularly chemotherapy) not only on noninfected but also on infected patients with cancer in accordance with cancer type, stage and prognosis, treatment agents, treatment setting, and SARS-CoV-2 infection risks.
Keyphrases
- respiratory syndrome coronavirus
- sars cov
- immune response
- coronavirus disease
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- locally advanced
- squamous cell carcinoma
- radiation therapy
- combination therapy
- peritoneal dialysis
- papillary thyroid
- prognostic factors
- palliative care
- rectal cancer
- inflammatory response
- smoking cessation
- advanced cancer
- patient reported